» Articles » PMID: 27559302

Age, Neurological Status MRC Scale, and Postoperative Morbidity Are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy

Abstract

Introduction: Temozolomide and concomitant radiotherapy followed by temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiform since 2005. A search for prognostic factors was conducted in patients with glioblastoma routinely treated by this strategy in our institution.

Methods: This retrospective study included all patients with histologically proven glioblastoma diagnosed between June 1, 2005, and January 1, 2012, in the Franche-Comté region and treated by radiotherapy (daily fractions of 2 Gy for a total of 60 Gy) combined with temozolomide at a dose of 75 mg/m(2) per day, followed by six cycles of maintenance temozolomide (150-200 mg/m(2), five consecutive days per month). The primary aim was to identify prognostic factors associated with overall survival (OS) in this cohort of patients.

Results: One hundred three patients were included in this study. The median age was 64 years. The median OS was 13.7 months (95% confidence interval, 12.5-15.9 months). In multivariate analysis, age over 65 years (hazard ratio [HR] = 1.88; P = 0.01), Medical Research Council (MRC) scale 3-4 (HR = 1.62; P = 0.038), and occurrence of postoperative complications (HR = 2.15; P = 0.028) were associated with unfavorable OS.

Conclusions: This study identified three prognostic factors in patients with glioblastoma eligible to the standard chemotherapy and radiotherapy treatment. Age over 65 years, MRC scale 3-4, and occurrence of postoperative complications were associated with unfavorable OS. A simple clinical evaluation including these three factors enables to estimate the patient prognosis. MRC neurological scale could be a useful, quick, and simple measure to assess neurological status in glioblastoma patients.

Citing Articles

Supramarginal Resection for Glioblastoma: It Is Time to Set Boundaries! A Critical Review on a Hot Topic.

Guerrini F, Roca E, Spena G Brain Sci. 2022; 12(5).

PMID: 35625037 PMC: 9139451. DOI: 10.3390/brainsci12050652.


The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients.

Kasper J, Wende T, Fehrenbach M, Wilhelmy F, Jahne K, Frydrychowicz C Front Oncol. 2021; 11:790458.

PMID: 34926307 PMC: 8674180. DOI: 10.3389/fonc.2021.790458.


A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy.

Cam Phuong P, Nam L, Schild S, Rades D, Khoa M In Vivo. 2017; 31(4):689-693.

PMID: 28652440 PMC: 5566923. DOI: 10.21873/invivo.11114.

References
1.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

2.
Bertolini F, Zunarelli E, Baraldi C, Valentini A, Del Giovane C, Depenni R . Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series. Tumori. 2013; 98(6):756-61. DOI: 10.1177/030089161209800613. View

3.
van Genugten J, Leffers P, Baumert B, Tjon-A-Fat H, Twijnstra A . Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol. 2009; 96(2):249-57. PMC: 2808536. DOI: 10.1007/s11060-009-9956-7. View

4.
Newlands E, OReilly S, Glaser M, Bower M, Evans H, Brock C . The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996; 32A(13):2236-41. DOI: 10.1016/s0959-8049(96)00258-4. View

5.
Jeon H, Kong D, Park K, Lee J, Park K, Kim J . Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg. 2009; 111(8):679-82. DOI: 10.1016/j.clineuro.2009.06.013. View